title: Risk Factors for Lung Cancer Mortality in a Referral Center.
abstract: BACKGROUND
  Lung cancer is one of the most common causes of death that is rising in many countries including Iran. This study aimed to determine the impact of factors on survival of lung cancer patients at a referral center of lung diseases in Tehran, Iran.
  
  
  METHODS
  A retrospective study was conducted on adult lung cancer cases admitted to a referral center for lung diseases from 2011 to 2015. Multivariate analysis was performed to determine the risk factors for all-cause mortality.
  
  
  RESULTS
  Of a total 933 patients with lung cancer, 53.4% died, 49.3% of them at the hospital. Overall median follow-up time was 7 months. The most common histological type of cancer was adenocarcinoma with a 13 month median survival time. Age ≥55 and smoking remained significant for all-cause mortality on Cox analysis, whereas gender was not.
  
  
  CONCLUSIONS
  The survival of lung cancer patients is poor and the patients with history of smoking and age ≥55 are at increased risk of death. Having a large hospital-based registry provides a good measurement of prognostic statistics for lung cancer. Further investigations are necessary to establish reasons for mortality.
authors.affiliation: Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran E-mail : adkhosravi@yahoo.com, pbaghaei@gmail.com.
authors.forename: H
authors.initials: H
authors.lastname: Jamaati
authors.forename: P
authors.initials: P
authors.lastname: Baghaei
authors.forename: M
authors.initials: M
authors.lastname: Sharifianfard
authors.forename: H
authors.initials: H
authors.lastname: Emami
authors.forename: K
authors.initials: K
authors.lastname: Najmi
authors.forename: S
authors.initials: S
authors.lastname: Seifi
authors.forename: B
authors.initials: B
authors.lastname: Salimi
authors.forename: M
authors.initials: M
authors.lastname: Pourabdollah
authors.forename: A
authors.initials: A
authors.lastname: Kiani
authors.forename: M
authors.initials: M
authors.lastname: Hashemian
authors.forename: A
authors.initials: A
authors.lastname: Khosravi
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D000328:Adult; D018287:Carcinoma, Large Cell / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012017:Referral and Consultation; D012189:Retrospective Studies; D012307:Risk Factors; D055752:Small Cell Lung Carcinoma / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D015996:Survival Rate